Nitrome emerges with $38M series A, platform for age-related diseases

Nitrome debuted Tuesday with a $38 million series A round, a platform targeting a newly identified class of enzymes dubbed nitrases and a lead program to treat Parkinson’s disease.

Sofinnova Partners and AbbVie Ventures co-led the round; the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments also participated. ...